Introduction
Medicinal plants and corresponding preparations have been used for a wide range of purposes and for many centuries people have been trying to treat diseases as well as alleviate symptoms by using different plant extracts and formulations (Cowan, 1999) . Plants such as Mentha piperita (Iscan et al., 2002) , Rosmarinus officinalis (Nascimento et al., 2000) , Arrabidaea chica (Taylor, 1998) , Tabebuia avellanedae (Machado et al., 2003) , Punica granatum (Nascimento et al., 2000; Duraipandiyan et al., 2006) and Syzygium cumini (Chandrasekaram and Venkatesalu, 2004) Screening for antimicrobial activities: Preparation of inoculum for susceptibility tests was carried out by microdilution as set forth by the CLSI's M27-A2 recommendation protocol (CLSI, 2002) . The yeasts were grown overnight at 37 °C in Sabouraud Dextrose Agar (Merck) plates, and inocula for the assays were prepared by diluting scrape cell mass in 0.85% NaCl solution, adjusted to 0.5 Mc Farland scale and confirmed by spectrophotometric reading at 625 nm. Cell suspensions were finally diluted to 5.0 × 10 3 CFU/mL. 50 µL of diluted extract were added in 50 µL of RPMI-1640 in microplates (96 wells) + 100 µL of microorganisms. After that, the samples were incubated at 37 °C for 24-48 hours, in duplicate. Fluconazol was used as control standard in concentrations ranging from 64-0.125 µg/mL. The microplates were incubated at 37 °C for 48 hours.
Results
All Candida species in the in vitro test presented sensitivity to the plant extracts in use, though not for all extracts (Table 1). mainly HIV-positive patients (Erköse and Erturan, 2007) . A particular characteristic of Candida is its ability to invade oral mucosa tissues by the development of hyphae, which adhere to tissue surfaces and lead to inflammation (Ellepola and Samaranayake, 2001) .
Although the colonisation by Candida albicans is common and causes severe injuries in immunocompromised patients, other Candida species have been isolated from such patients, healthy patients and children with Down's syndrome, such as C. glabrata, C. krusei, C. tropicalis, C. lusitaniae, C. parapsilosis, C. guilliermondii (Erköse and Erturan, 2007; Höfling et al., 2001; Ribeiro et al., 2006; Rodrigues et al., 2004) and C. dubliniensis. These yeasts were recognised as the source of mucosal infection in HIV-positive patients and regarded as a significant cause of infections in humans, such as abdominal infections and fungemia (Erköse and Erturan, 2007) .
The purpose of this study was to evaluate the potential activity of extracts from six selected plants against ten Candida species. Preparation of extracts: Each selected plant (5 g) was extracted with 600 mL of dichloromethane (Labsynth PA) with a Dispersive Extratur (Quimis ® Q-252-28 model) and activity. Punica granatum and Syzygium cumini extracts exerted strong antifungal activity and can be a source for the development of new therapeutic agents, as they inhibited the growth of Candida. Subsequently, bioguided fractionation shall be conducted on Puninca granatum to identify the active compounds against Candida genus species.
Material and Methods

